---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-194907"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:35:46.379683+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cytek Q2 revenue $46.6M, -6% YoY; net loss widens to $10.4M

## Summary
- Revenue $46.6M (-6% YoY, +4% QoQ); GAAP gross margin 55% (adjusted 58%).
- Net loss $10.4M vs $4.4M in Q2 2023; operating loss $8.5M vs $9.1M.
- Adjusted EBITDA $2.9M vs $1.5M; cash and securities $277.2M.
- FY2024 revenue guidance narrowed to $203-210M (5-9% growth); expects positive cash flow from ops.
- Repurchased $2.7M of stock; total installed base 2,656 instruments.

## SEC filing metadata
- accession: 0001193125-24-194907
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312524194907/0001193125-24-194907-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312524194907/d859161d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-194907
- JSON: https://secwatch.observer/filing/0001193125-24-194907.json
- Plain text: https://secwatch.observer/filing/0001193125-24-194907.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.